Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD

Exclusion Criteria

• •General Criteria:
• •1. Concurrent illness other than DMD that can cause muscle weakness and/or impairment of motor function
• •2. Severe intellectual impairment (for example, severe autism, severe cognitive impairment, severe behavioral disturbances) preventing the ability to perform study assessments in the Investigator's judgment
• •3. Previous exposure to pamrevlumab
• •4. Body mass index (BMI) ≥40 kg/square meter (m\^2) or weight \>117 kg
• •5. History of
• •1. allergic or anaphylactic reaction to human, humanized, chimeric or murine monoclonal antibodies
• •2. hypersensitivity to study drug or any component of study drug
• •6. Exposure to any investigational drug (for DMD or not), in the 30 days prior to screening initiation or use of approved DMD therapies (for example, eteplirsen, ataluren, golodirsen, casimersen) within 5 half-lives of screening, whichever is longer with the exception of the systemic corticosteroids, including deflazacort
• •Pulmonary and Cardiac criteria:
• •7. Requires ≥16 hours continuous ventilation
• •8. Poorly controlled asthma or underlying lung disease such as bronchitis, bronchiectasis, emphysema, recurrent pneumonia that in the opinion of the investigator might impact respiratory function
• •9. Hospitalization due to respiratory failure within the 8 weeks prior to screening
• •10. Severe uncontrolled heart failure (New York Heart Association \[NYHA\] Classes III-IV) or renal dysfunction, including any of the following:
• •1. Need for intravenous diuretics or inotropic support within 8 weeks prior to screening
• •2. Hospitalization for a heart failure exacerbation or arrhythmia within 8 weeks prior to screening
• •3. Participants with glomerular filtration rate (GFR) of less than 30 mL/minute (min)/1.73 m\^2 or with other evidence of acute kidney injury as determined by investigator
• •11. Arrhythmia requiring anti-arrhythmic therapy
• •12. Any other evidence of clinically significant structural or functional heart abnormality
• •Clinical judgment:
• •13. The Investigator judges that the participant will be unable to fully participate in the study and complete it for any reason, including inability to comply with study procedures and treatment, or any other relevant medical, surgical or psychiatric conditions